{"transactions":[{"id":876474,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":64215,"kind":"person","name":"Jacquet Pierre","position":1,"cik":"0001783451","reported_name":"Jacquet Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Restricted Stock Units","published_at":"2026-02-27T21:30:32.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":106848,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":106848,"derivative":{"underlying":"American Depository Shares","underlying_shares":106848},"source":{"system":"sec-edgar","filing":"0001193125-26-082831","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1719714/000119312526082831/ownership.xml","form_type":"4"}},{"id":876473,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":64215,"kind":"person","name":"Jacquet Pierre","position":1,"cik":"0001783451","reported_name":"Jacquet Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to buy)","published_at":"2026-02-27T21:30:32.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":66000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":66000,"derivative":{"exercise_price":0.39,"expiration_date":"2036-02-26","underlying":"American Depositary Shares","underlying_shares":66000},"source":{"system":"sec-edgar","filing":"0001193125-26-082831","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1719714/000119312526082831/ownership.xml","form_type":"4"}},{"id":876536,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":29693,"kind":"person","name":"Yoskowitz Marc J","position":1,"cik":"0001617306","reported_name":"Yoskowitz Marc J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Restricted Stock Units","published_at":"2026-02-27T21:30:29.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":96163,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":96163,"derivative":{"underlying":"American Depository Shares","underlying_shares":96163},"source":{"system":"sec-edgar","filing":"0001193125-26-082830","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1617306/000119312526082830/ownership.xml","form_type":"4"}},{"id":876535,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":29693,"kind":"person","name":"Yoskowitz Marc J","position":1,"cik":"0001617306","reported_name":"Yoskowitz Marc J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to buy)","published_at":"2026-02-27T21:30:29.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":66000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":66000,"derivative":{"exercise_price":0.39,"expiration_date":"2036-02-26","underlying":"American Depositary Shares","underlying_shares":66000},"source":{"system":"sec-edgar","filing":"0001193125-26-082830","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1617306/000119312526082830/ownership.xml","form_type":"4"}},{"id":878502,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Restricted Stock Units","published_at":"2026-02-27T21:30:15.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":117533,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":117533,"derivative":{"underlying":"American Depository Shares","underlying_shares":117533},"source":{"system":"sec-edgar","filing":"0001193125-26-082838","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000119312526082838/ownership.xml","form_type":"4"}},{"id":878501,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to buy)","published_at":"2026-02-27T21:30:15.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":66000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":66000,"derivative":{"exercise_price":0.39,"expiration_date":"2036-02-26","underlying":"American Depositary Shares","underlying_shares":66000},"source":{"system":"sec-edgar","filing":"0001193125-26-082838","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000119312526082838/ownership.xml","form_type":"4"}},{"id":876999,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to buy)","published_at":"2026-02-27T21:30:13.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":66000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":66000,"derivative":{"exercise_price":0.39,"expiration_date":"2036-02-26","underlying":"American Depositary Shares","underlying_shares":66000},"source":{"system":"sec-edgar","filing":"0001193125-26-082818","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000119312526082818/ownership.xml","form_type":"4"}},{"id":876501,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":54212,"kind":"person","name":"Jenkins Annalisa","position":1,"cik":"0001639481","reported_name":"Jenkins Annalisa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Restricted Stock Units","published_at":"2026-02-27T21:30:09.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":106848,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":106848,"derivative":{"underlying":"American Depository Shares","underlying_shares":106848},"source":{"system":"sec-edgar","filing":"0001193125-26-082835","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1639481/000119312526082835/ownership.xml","form_type":"4"}},{"id":876500,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":54212,"kind":"person","name":"Jenkins Annalisa","position":1,"cik":"0001639481","reported_name":"Jenkins Annalisa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to buy)","published_at":"2026-02-27T21:30:09.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":66000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":66000,"derivative":{"exercise_price":0.39,"expiration_date":"2036-02-26","underlying":"American Depositary Shares","underlying_shares":66000},"source":{"system":"sec-edgar","filing":"0001193125-26-082835","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1639481/000119312526082835/ownership.xml","form_type":"4"}},{"id":876967,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to buy)","published_at":"2026-02-27T21:30:08.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":66000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":66000,"derivative":{"exercise_price":0.39,"expiration_date":"2036-02-26","underlying":"American Depositary Shares","underlying_shares":66000},"source":{"system":"sec-edgar","filing":"0001193125-26-082815","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000119312526082815/ownership.xml","form_type":"4"}},{"id":877605,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":64278,"kind":"person","name":"Shames Daniel","position":1,"cik":"0002005702","reported_name":"Shames Daniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Restricted Stock Units","published_at":"2026-02-27T16:30:24.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":96163,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":96163,"derivative":{"underlying":"American Depository Shares","underlying_shares":96163},"source":{"system":"sec-edgar","filing":"0001193125-26-082826","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2005702/000119312526082826/ownership.xml","form_type":"4"}},{"id":877604,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":64278,"kind":"person","name":"Shames Daniel","position":1,"cik":"0002005702","reported_name":"Shames Daniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to buy)","published_at":"2026-02-27T16:30:24.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":66000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":66000,"derivative":{"exercise_price":0.39,"expiration_date":"2036-02-26","underlying":"American Depositary Shares","underlying_shares":66000},"source":{"system":"sec-edgar","filing":"0001193125-26-082826","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005702/000119312526082826/ownership.xml","form_type":"4"}},{"id":877607,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":64279,"kind":"person","name":"Ekblom Anders","position":1,"cik":"0002005817","reported_name":"Ekblom Anders","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Restricted Stock Units","published_at":"2026-02-27T16:30:16.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":133560,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":133560,"derivative":{"underlying":"American Depository Shares","underlying_shares":133560},"source":{"system":"sec-edgar","filing":"0001193125-26-082820","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2005817/000119312526082820/ownership.xml","form_type":"4"}},{"id":877606,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":64279,"kind":"person","name":"Ekblom Anders","position":1,"cik":"0002005817","reported_name":"Ekblom Anders","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to buy)","published_at":"2026-02-27T16:30:16.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":66000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":66000,"derivative":{"exercise_price":0.39,"expiration_date":"2036-02-26","underlying":"American Depositary Shares","underlying_shares":66000},"source":{"system":"sec-edgar","filing":"0001193125-26-082820","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005817/000119312526082820/ownership.xml","form_type":"4"}},{"id":924754,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":44173,"kind":"person","name":"Scots-Knight Denise","position":1,"cik":"0001297000","reported_name":"Scots-Knight Denise","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Share Options (Right to buy)","published_at":"2026-02-02T21:30:05.000Z","date":"2026-02-01","kind":"grant","planned":false,"acquired":true,"shares":480000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Vests in substantially equal monthly installments over a one year period from the February 1, 2026 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":480000,"derivative":{"exercise_price":0.44,"expiration_date":"2036-02-01","underlying":"American Depository Shares","underlying_shares":480000},"source":{"system":"sec-edgar","filing":"0001193125-26-033751","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1297000/000119312526033751/ownership.xml","form_type":"4"}},{"id":924753,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":44173,"kind":"person","name":"Scots-Knight Denise","position":1,"cik":"0001297000","reported_name":"Scots-Knight Denise","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Share Options (Right to buy)","published_at":"2026-02-02T21:30:05.000Z","date":"2026-02-01","kind":"grant","planned":false,"acquired":true,"shares":345000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":345000,"derivative":{"exercise_price":1,"expiration_date":"2036-02-01","underlying":"American Depository Shares","underlying_shares":345000},"source":{"system":"sec-edgar","filing":"0001193125-26-033751","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1297000/000119312526033751/ownership.xml","form_type":"4"}},{"id":924752,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":44173,"kind":"person","name":"Scots-Knight Denise","position":1,"cik":"0001297000","reported_name":"Scots-Knight Denise","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Share Options (Right to buy)","published_at":"2026-02-02T21:30:05.000Z","date":"2026-02-01","kind":"grant","planned":false,"acquired":true,"shares":1035000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":1035000,"derivative":{"exercise_price":0.44,"expiration_date":"2036-02-01","underlying":"American Depositary Shares","underlying_shares":1035000},"source":{"system":"sec-edgar","filing":"0001193125-26-033751","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1297000/000119312526033751/ownership.xml","form_type":"4"}},{"id":924552,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Share Options (Right to buy)","published_at":"2026-02-02T16:30:10.000Z","date":"2026-02-01","kind":"grant","planned":false,"acquired":true,"shares":145000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Vests in substantially equal monthly installments over a one year period from the February 1, 2026 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":145000,"derivative":{"exercise_price":0.44,"expiration_date":"2036-02-01","underlying":"American Depository Shares","underlying_shares":145000},"source":{"system":"sec-edgar","filing":"0001193125-26-033754","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553352/000119312526033754/ownership.xml","form_type":"4"}},{"id":924551,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Share Options (Right to buy)","published_at":"2026-02-02T16:30:10.000Z","date":"2026-02-01","kind":"grant","planned":false,"acquired":true,"shares":46637,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":46637,"derivative":{"exercise_price":1,"expiration_date":"2036-02-01","underlying":"American Depository Shares","underlying_shares":46637},"source":{"system":"sec-edgar","filing":"0001193125-26-033754","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553352/000119312526033754/ownership.xml","form_type":"4"}},{"id":924550,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Share Options (Right to buy)","published_at":"2026-02-02T16:30:10.000Z","date":"2026-02-01","kind":"grant","planned":false,"acquired":true,"shares":139913,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":139913,"derivative":{"exercise_price":0.44,"expiration_date":"2036-02-01","underlying":"American Depositary Shares","underlying_shares":139913},"source":{"system":"sec-edgar","filing":"0001193125-26-033754","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553352/000119312526033754/ownership.xml","form_type":"4"}},{"id":925518,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68234,"kind":"person","name":"Hughes-Wilson Alexandra","position":1,"cik":"0002005875","reported_name":"Hughes-Wilson Alexandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Share Options (Right to buy)","published_at":"2026-02-02T16:30:08.000Z","date":"2026-02-01","kind":"grant","planned":false,"acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Vests in substantially equal monthly installments over a one year period from the February 1, 2026 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":195000,"derivative":{"exercise_price":0.44,"expiration_date":"2036-02-01","underlying":"American Depository Shares","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0001193125-26-033753","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2005875/000119312526033753/ownership.xml","form_type":"4"}},{"id":925517,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68234,"kind":"person","name":"Hughes-Wilson Alexandra","position":1,"cik":"0002005875","reported_name":"Hughes-Wilson Alexandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Share Options (Right to buy)","published_at":"2026-02-02T16:30:08.000Z","date":"2026-02-01","kind":"grant","planned":false,"acquired":true,"shares":61250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":61250,"derivative":{"exercise_price":1,"expiration_date":"2036-02-01","underlying":"American Depository Shares","underlying_shares":61250},"source":{"system":"sec-edgar","filing":"0001193125-26-033753","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2005875/000119312526033753/ownership.xml","form_type":"4"}},{"id":925516,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68234,"kind":"person","name":"Hughes-Wilson Alexandra","position":1,"cik":"0002005875","reported_name":"Hughes-Wilson Alexandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Share Options (Right to buy)","published_at":"2026-02-02T16:30:08.000Z","date":"2026-02-01","kind":"grant","planned":false,"acquired":true,"shares":183750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":183750,"derivative":{"exercise_price":0.44,"expiration_date":"2036-02-01","underlying":"American Depositary Shares","underlying_shares":183750},"source":{"system":"sec-edgar","filing":"0001193125-26-033753","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005875/000119312526033753/ownership.xml","form_type":"4"}},{"id":925084,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68213,"kind":"person","name":"Sermon Charles","position":1,"cik":"0001687318","reported_name":"Sermon Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Share Options (Right to buy)","published_at":"2026-02-02T16:30:07.000Z","date":"2026-02-01","kind":"grant","planned":false,"acquired":true,"shares":295000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Vests in substantially equal monthly installments over a one year period from the February 1, 2026 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":295000,"derivative":{"exercise_price":0.44,"expiration_date":"2036-02-01","underlying":"American Depository Shares","underlying_shares":295000},"source":{"system":"sec-edgar","filing":"0001193125-26-033752","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1687318/000119312526033752/ownership.xml","form_type":"4"}},{"id":925083,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68213,"kind":"person","name":"Sermon Charles","position":1,"cik":"0001687318","reported_name":"Sermon Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Share Options (Right to buy)","published_at":"2026-02-02T16:30:07.000Z","date":"2026-02-01","kind":"grant","planned":false,"acquired":true,"shares":105250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":105250,"derivative":{"exercise_price":1,"expiration_date":"2036-02-01","underlying":"American Depository Shares","underlying_shares":105250},"source":{"system":"sec-edgar","filing":"0001193125-26-033752","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1687318/000119312526033752/ownership.xml","form_type":"4"}},{"id":925082,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68213,"kind":"person","name":"Sermon Charles","position":1,"cik":"0001687318","reported_name":"Sermon Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Share Options (Right to buy)","published_at":"2026-02-02T16:30:07.000Z","date":"2026-02-01","kind":"grant","planned":false,"acquired":true,"shares":315750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":315750,"derivative":{"exercise_price":0.44,"expiration_date":"2036-02-01","underlying":"American Depositary Shares","underlying_shares":315750},"source":{"system":"sec-edgar","filing":"0001193125-26-033752","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1687318/000119312526033752/ownership.xml","form_type":"4"}},{"id":925522,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68235,"kind":"person","name":"Fox Christine Ann","position":1,"cik":"0002005755","reported_name":"Fox Christine Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Share Options (Right to buy)","published_at":"2026-02-02T16:30:04.000Z","date":"2026-02-01","kind":"grant","planned":false,"acquired":true,"shares":280000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Vests in substantially equal monthly installments over a one year period from the February 1, 2026 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":280000,"derivative":{"exercise_price":0.44,"expiration_date":"2036-02-01","underlying":"American Depository Shares","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0001193125-26-033749","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2005755/000119312526033749/ownership.xml","form_type":"4"}},{"id":925521,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68235,"kind":"person","name":"Fox Christine Ann","position":1,"cik":"0002005755","reported_name":"Fox Christine Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Share Options (Right to buy)","published_at":"2026-02-02T16:30:04.000Z","date":"2026-02-01","kind":"grant","planned":false,"acquired":true,"shares":105250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":105250,"derivative":{"exercise_price":1,"expiration_date":"2036-02-01","underlying":"American Depository Shares","underlying_shares":105250},"source":{"system":"sec-edgar","filing":"0001193125-26-033749","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2005755/000119312526033749/ownership.xml","form_type":"4"}},{"id":925520,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68235,"kind":"person","name":"Fox Christine Ann","position":1,"cik":"0002005755","reported_name":"Fox Christine Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Share Options (Right to buy)","published_at":"2026-02-02T16:30:04.000Z","date":"2026-02-01","kind":"grant","planned":false,"acquired":true,"shares":315750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":315750,"derivative":{"exercise_price":0.44,"expiration_date":"2036-02-01","underlying":"American Depositary Shares","underlying_shares":315750},"source":{"system":"sec-edgar","filing":"0001193125-26-033749","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005755/000119312526033749/ownership.xml","form_type":"4"}},{"id":1280008,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":29693,"kind":"person","name":"Yoskowitz Marc J","position":1,"cik":"0001617306","reported_name":"Yoskowitz Marc J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Restricted Stock Units","published_at":"2025-02-06T21:30:22.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":13719,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer"}],"balance_after":13719,"derivative":{"underlying":"American Depository Shares","underlying_shares":13719},"source":{"system":"sec-edgar","filing":"0000950170-25-015426","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1617306/000095017025015426/ownership.xml","form_type":"4"}},{"id":1280007,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":29693,"kind":"person","name":"Yoskowitz Marc J","position":1,"cik":"0001617306","reported_name":"Yoskowitz Marc J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to buy)","published_at":"2025-02-06T21:30:22.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in substantially equal monthly installments over a one year period from the February 5, 2025 grant date"},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer"}],"balance_after":55000,"derivative":{"exercise_price":3.16,"expiration_date":"2035-02-05","underlying":"American Depositary Shares","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000950170-25-015426","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1617306/000095017025015426/ownership.xml","form_type":"4"}},{"id":1280172,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to buy)","published_at":"2025-02-06T21:30:15.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in substantially equal monthly installments over a one year period from the February 5, 2025 grant date"},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer"}],"balance_after":55000,"derivative":{"exercise_price":3.16,"expiration_date":"2035-02-05","underlying":"American Depositary Shares","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000950170-25-015423","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017025015423/ownership.xml","form_type":"4"}},{"id":1280813,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Restricted Stock Units","published_at":"2025-02-06T21:30:14.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":16768,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer"}],"balance_after":16768,"derivative":{"underlying":"American Depository Shares","underlying_shares":16768},"source":{"system":"sec-edgar","filing":"0000950170-25-015433","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000095017025015433/ownership.xml","form_type":"4"}},{"id":1280812,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28118,"kind":"person","name":"Bender Jeremy","position":1,"cik":"0001863107","reported_name":"Bender Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to buy)","published_at":"2025-02-06T21:30:14.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in substantially equal monthly installments over a one year period from the February 5, 2025 grant date"},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer"}],"balance_after":55000,"derivative":{"exercise_price":3.16,"expiration_date":"2035-02-05","underlying":"American Depositary Shares","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000950170-25-015433","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863107/000095017025015433/ownership.xml","form_type":"4"}},{"id":1280161,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Restricted Stock Units","published_at":"2025-02-06T21:30:06.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":30487,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer"}],"balance_after":30487,"derivative":{"underlying":"American Depository Shares","underlying_shares":30487},"source":{"system":"sec-edgar","filing":"0000950170-25-015418","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000095017025015418/ownership.xml","form_type":"4"}},{"id":1280160,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":39203,"kind":"person","name":"WYZGA MICHAEL S","position":1,"cik":"0001201256","reported_name":"WYZGA MICHAEL S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to buy)","published_at":"2025-02-06T21:30:06.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in substantially equal monthly installments over a one year period from the February 5, 2025 grant date"},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer"}],"balance_after":55000,"derivative":{"exercise_price":3.16,"expiration_date":"2035-02-05","underlying":"American Depositary Shares","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000950170-25-015418","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1201256/000095017025015418/ownership.xml","form_type":"4"}},{"id":1280004,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":54212,"kind":"person","name":"Jenkins Annalisa","position":1,"cik":"0001639481","reported_name":"Jenkins Annalisa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Restricted Stock Units","published_at":"2025-02-06T21:30:05.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":15243,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer"}],"balance_after":15243,"derivative":{"underlying":"American Depository Shares","underlying_shares":15243},"source":{"system":"sec-edgar","filing":"0000950170-25-015417","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1639481/000095017025015417/ownership.xml","form_type":"4"}},{"id":1280003,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":54212,"kind":"person","name":"Jenkins Annalisa","position":1,"cik":"0001639481","reported_name":"Jenkins Annalisa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to buy)","published_at":"2025-02-06T21:30:05.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in substantially equal monthly installments over a one year period from the February 5, 2025 grant date"},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer"}],"balance_after":55000,"derivative":{"exercise_price":3.16,"expiration_date":"2035-02-05","underlying":"American Depositary Shares","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000950170-25-015417","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1639481/000095017025015417/ownership.xml","form_type":"4"}},{"id":1279988,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":64215,"kind":"person","name":"Jacquet Pierre","position":1,"cik":"0001783451","reported_name":"Jacquet Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Restricted Stock Units","published_at":"2025-02-06T21:30:04.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":15243,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer"}],"balance_after":15243,"derivative":{"underlying":"American Depository Shares","underlying_shares":15243},"source":{"system":"sec-edgar","filing":"0000950170-25-015427","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1719714/000095017025015427/ownership.xml","form_type":"4"}},{"id":1279987,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":64215,"kind":"person","name":"Jacquet Pierre","position":1,"cik":"0001783451","reported_name":"Jacquet Pierre","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to buy)","published_at":"2025-02-06T21:30:04.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in substantially equal monthly installments over a one year period from the February 5, 2025 grant date"},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer"}],"balance_after":55000,"derivative":{"exercise_price":3.16,"expiration_date":"2035-02-05","underlying":"American Depositary Shares","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000950170-25-015427","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1719714/000095017025015427/ownership.xml","form_type":"4"}},{"id":1280480,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":64279,"kind":"person","name":"Ekblom Anders","position":1,"cik":"0002005817","reported_name":"Ekblom Anders","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Restricted Stock Units","published_at":"2025-02-06T16:30:08.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":19054,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer"}],"balance_after":19054,"derivative":{"underlying":"American Depository Shares","underlying_shares":19054},"source":{"system":"sec-edgar","filing":"0000950170-25-015419","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2005817/000095017025015419/ownership.xml","form_type":"4"}},{"id":1280479,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":64279,"kind":"person","name":"Ekblom Anders","position":1,"cik":"0002005817","reported_name":"Ekblom Anders","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to buy)","published_at":"2025-02-06T16:30:08.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in substantially equal monthly installments over a one year period from the February 5, 2025 grant date"},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer"}],"balance_after":55000,"derivative":{"exercise_price":3.16,"expiration_date":"2035-02-05","underlying":"American Depositary Shares","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000950170-25-015419","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005817/000095017025015419/ownership.xml","form_type":"4"}},{"id":1280478,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":64278,"kind":"person","name":"Shames Daniel","position":1,"cik":"0002005702","reported_name":"Shames Daniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Deferred Restricted Stock Units","published_at":"2025-02-06T16:30:06.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":13719,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Deferred restricted stock units (\"DRSU\") are granted to non-executive directors who elected to receive DRSUs in the form of ADSs in lieu of annual cash compensation. DRSUs vest in substantially equal monthly installments over the plan year following the grant date. Payment of DRSUs in ADSs will generally be made 180 days following separation of service."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer"}],"balance_after":13719,"derivative":{"underlying":"American Depository Shares","underlying_shares":13719},"source":{"system":"sec-edgar","filing":"0000950170-25-015428","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2005702/000095017025015428/ownership.xml","form_type":"4"}},{"id":1280477,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":64278,"kind":"person","name":"Shames Daniel","position":1,"cik":"0002005702","reported_name":"Shames Daniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (Right to buy)","published_at":"2025-02-06T16:30:06.000Z","date":"2025-02-05","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in substantially equal monthly installments over a one year period from the February 5, 2025 grant date"},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer"}],"balance_after":55000,"derivative":{"exercise_price":3.16,"expiration_date":"2035-02-05","underlying":"American Depositary Shares","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000950170-25-015428","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005702/000095017025015428/ownership.xml","form_type":"4"}},{"id":1292931,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":44173,"kind":"person","name":"Scots-Knight Denise","position":1,"cik":"0001297000","reported_name":"Scots-Knight Denise","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Share Options (Right to buy)","published_at":"2025-01-28T21:05:03.000Z","date":"2025-01-25","kind":"grant","planned":false,"acquired":true,"shares":825000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this share option will vest and become exercisable on January 25, 2026, with the remainder vesting in equal monthly installments for the three years thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":825000,"derivative":{"exercise_price":2.91,"expiration_date":"2035-01-25","underlying":"American Depository Shares","underlying_shares":825000},"source":{"system":"sec-edgar","filing":"0000950170-25-009787","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1297000/000095017025009787/ownership.xml","form_type":"4"}},{"id":1292838,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Share Options (Right to buy)","published_at":"2025-01-28T16:05:15.000Z","date":"2025-01-25","kind":"grant","planned":false,"acquired":true,"shares":116000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this share option will vest and become exercisable on January 25, 2026, with the remainder vesting in equal monthly installments for the three years thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":116000,"derivative":{"exercise_price":2.91,"expiration_date":"2035-01-25","underlying":"American Depository Shares","underlying_shares":116000},"source":{"system":"sec-edgar","filing":"0000950170-25-009794","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553352/000095017025009794/ownership.xml","form_type":"4"}},{"id":1293253,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68235,"kind":"person","name":"Fox Christine Ann","position":1,"cik":"0002005755","reported_name":"Fox Christine Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Share Options (Right to buy)","published_at":"2025-01-28T16:05:13.000Z","date":"2025-01-25","kind":"grant","planned":false,"acquired":true,"shares":262000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this share option will vest and become exercisable on January 25, 2026, with the remainder vesting in equal monthly installments for the three years thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":262000,"derivative":{"exercise_price":2.91,"expiration_date":"2035-01-25","underlying":"American Depository Shares","underlying_shares":262000},"source":{"system":"sec-edgar","filing":"0000950170-25-009793","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005755/000095017025009793/ownership.xml","form_type":"4"}},{"id":1293080,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68213,"kind":"person","name":"Sermon Charles","position":1,"cik":"0001687318","reported_name":"Sermon Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Share Options (Right to buy)","published_at":"2025-01-28T16:05:10.000Z","date":"2025-01-25","kind":"grant","planned":false,"acquired":true,"shares":262000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this share option will vest and become exercisable on January 25, 2026, with the remainder vesting in equal monthly installments for the three years thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":262000,"derivative":{"exercise_price":2.91,"expiration_date":"2035-01-25","underlying":"American Depository Shares","underlying_shares":262000},"source":{"system":"sec-edgar","filing":"0000950170-25-009791","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1687318/000095017025009791/ownership.xml","form_type":"4"}},{"id":1293252,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68234,"kind":"person","name":"Hughes-Wilson Alexandra","position":1,"cik":"0002005875","reported_name":"Hughes-Wilson Alexandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Share Options (Right to buy)","published_at":"2025-01-28T16:05:07.000Z","date":"2025-01-25","kind":"grant","planned":false,"acquired":true,"shares":154000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this share option will vest and become exercisable on January 25, 2026, with the remainder vesting in equal monthly installments for the three years thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":154000,"derivative":{"exercise_price":2.91,"expiration_date":"2035-01-25","underlying":"American Depository Shares","underlying_shares":154000},"source":{"system":"sec-edgar","filing":"0000950170-25-009789","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005875/000095017025009789/ownership.xml","form_type":"4"}},{"id":1406549,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":44173,"kind":"person","name":"Scots-Knight Denise","position":1,"cik":"0001297000","reported_name":"Scots-Knight Denise","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-09-17T00:50:10.000Z","date":"2024-09-13","kind":"sale","planned":false,"acquired":false,"shares":60046,"price":4.221,"value":253454.166,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on September 11, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.01 to $4.43, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes 1,200 ADSs jointly owned by Reporting person and her spouse."}],"balance_after":808921,"source":{"system":"sec-edgar","filing":"0000950170-24-106976","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1297000/000095017024106976/ownership.xml","form_type":"4"}},{"id":1406548,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":44173,"kind":"person","name":"Scots-Knight Denise","position":1,"cik":"0001297000","reported_name":"Scots-Knight Denise","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-09-17T00:50:10.000Z","date":"2024-09-12","kind":"sale","planned":false,"acquired":false,"shares":28611,"price":4.4727,"value":127968.4197,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"Reporting Person also beneficially owns 4 ordinary shares, nominal value of GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on September 11, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.37 to $4.62, inclusive. The Reporting Person undertakes to provide to Mereo BioPharma Group plc (\"Mereo\"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (4) and (5) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes 1,200 ADSs jointly owned by Reporting person and her spouse."}],"balance_after":868967,"source":{"system":"sec-edgar","filing":"0000950170-24-106976","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1297000/000095017024106976/ownership.xml","form_type":"4"}},{"id":1406424,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-09-16T20:49:03.000Z","date":"2024-09-13","kind":"sale","planned":false,"acquired":false,"shares":10937,"price":4.221,"value":46165.077,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on September 11, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.01 to $4.43, inclusive."}],"balance_after":78630,"source":{"system":"sec-edgar","filing":"0000950170-24-106974","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553352/000095017024106974/ownership.xml","form_type":"4"}},{"id":1406423,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-09-16T20:49:03.000Z","date":"2024-09-12","kind":"sale","planned":false,"acquired":false,"shares":5212,"price":4.4727,"value":23311.7124,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on September 11, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.37 to $4.62, inclusive. The Reporting Person undertakes to provide to Mereo BioPharma Group plc (\"Mereo\"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4."}],"balance_after":89567,"source":{"system":"sec-edgar","filing":"0000950170-24-106974","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553352/000095017024106974/ownership.xml","form_type":"4"}},{"id":1406653,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68213,"kind":"person","name":"Sermon Charles","position":1,"cik":"0001687318","reported_name":"Sermon Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-09-16T20:48:57.000Z","date":"2024-09-13","kind":"sale","planned":false,"acquired":false,"shares":20946,"price":4.221,"value":88413.066,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on September 11, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.01 to $4.43, inclusive."}],"balance_after":219061,"source":{"system":"sec-edgar","filing":"0000950170-24-106972","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1687318/000095017024106972/ownership.xml","form_type":"4"}},{"id":1406652,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68213,"kind":"person","name":"Sermon Charles","position":1,"cik":"0001687318","reported_name":"Sermon Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-09-16T20:48:57.000Z","date":"2024-09-12","kind":"sale","planned":false,"acquired":false,"shares":9980,"price":4.4727,"value":44637.546,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"Reporting Person also beneficially owns 4 ordinary shares, nominal value of GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on September 11, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.37 to $4.62, inclusive. The Reporting Person undertakes to provide to Mereo BioPharma Group plc (\"Mereo\"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (4) and (5) to this Form 4."}],"balance_after":240007,"source":{"system":"sec-edgar","filing":"0000950170-24-106972","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1687318/000095017024106972/ownership.xml","form_type":"4"}},{"id":1406844,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68235,"kind":"person","name":"Fox Christine Ann","position":1,"cik":"0002005755","reported_name":"Fox Christine Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-09-16T20:47:45.000Z","date":"2024-09-13","kind":"sale","planned":false,"acquired":false,"shares":19158,"price":4.221,"value":80865.918,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on September 11, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.01 to $4.43, inclusive."}],"balance_after":89285,"source":{"system":"sec-edgar","filing":"0000950170-24-106970","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2005755/000095017024106970/ownership.xml","form_type":"4"}},{"id":1406843,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68235,"kind":"person","name":"Fox Christine Ann","position":1,"cik":"0002005755","reported_name":"Fox Christine Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-09-16T20:47:45.000Z","date":"2024-09-12","kind":"sale","planned":false,"acquired":false,"shares":9128,"price":4.4727,"value":40826.8056,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on September 11, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.37 to $4.62, inclusive. The Reporting Person undertakes to provide to Mereo BioPharma Group plc (\"Mereo\"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4."}],"balance_after":108443,"source":{"system":"sec-edgar","filing":"0000950170-24-106970","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005755/000095017024106970/ownership.xml","form_type":"4"}},{"id":1406842,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68234,"kind":"person","name":"Hughes-Wilson Alexandra","position":1,"cik":"0002005875","reported_name":"Hughes-Wilson Alexandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-09-16T20:46:34.000Z","date":"2024-09-13","kind":"sale","planned":false,"acquired":false,"shares":84008,"price":4.221,"value":354597.768,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F5","text":"The Reporting Person sold a total of 124,037 ADSs solely to pay tax obligations, including tax withholding obligations related to the exercise of stock options described in the Form 4 filed on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.01 to $4.43, inclusive."}],"balance_after":50475,"source":{"system":"sec-edgar","filing":"0000950170-24-106968","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2005875/000095017024106968/ownership.xml","form_type":"4"}},{"id":1406841,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68234,"kind":"person","name":"Hughes-Wilson Alexandra","position":1,"cik":"0002005875","reported_name":"Hughes-Wilson Alexandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-09-16T20:46:34.000Z","date":"2024-09-13","kind":"sale","planned":false,"acquired":false,"shares":16304,"price":4.221,"value":68819.184,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the 'Plan'), occurring on September 11, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.01 to $4.43, inclusive."}],"balance_after":134483,"source":{"system":"sec-edgar","filing":"0000950170-24-106968","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2005875/000095017024106968/ownership.xml","form_type":"4"}},{"id":1406840,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68234,"kind":"person","name":"Hughes-Wilson Alexandra","position":1,"cik":"0002005875","reported_name":"Hughes-Wilson Alexandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-09-16T20:46:34.000Z","date":"2024-09-12","kind":"sale","planned":false,"acquired":false,"shares":40029,"price":4.4727,"value":179037.7083,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F5","text":"The Reporting Person sold a total of 124,037 ADSs solely to pay tax obligations, including tax withholding obligations related to the exercise of stock options described in the Form 4 filed on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.37 to $4.62, inclusive. The Reporting Person undertakes to provide to Mereo BioPharma Group plc (\"Mereo\"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4."}],"balance_after":150787,"source":{"system":"sec-edgar","filing":"0000950170-24-106968","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2005875/000095017024106968/ownership.xml","form_type":"4"}},{"id":1406839,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68234,"kind":"person","name":"Hughes-Wilson Alexandra","position":1,"cik":"0002005875","reported_name":"Hughes-Wilson Alexandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-09-16T20:46:34.000Z","date":"2024-09-12","kind":"sale","planned":false,"acquired":false,"shares":7769,"price":4.4727,"value":34748.4063,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the 'Plan'), occurring on September 11, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.37 to $4.62, inclusive. The Reporting Person undertakes to provide to Mereo BioPharma Group plc (\"Mereo\"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The total amount of securities beneficially owned on the reporting person's Form 4 filed on September 13, 2024 has been reduced by 44,296, which reflects ADSs withheld by the Issuer in connection with the net settlement of the stock option exercise on September 11, 2024 and inadvertently omitted from the September 13, 2024 filing. Such withholding is exempt from Section 16(b) pursuant to Rule 16b-3."}],"balance_after":190816,"source":{"system":"sec-edgar","filing":"0000950170-24-106968","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005875/000095017024106968/ownership.xml","form_type":"4"}},{"id":1407553,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":44173,"kind":"person","name":"Scots-Knight Denise","position":1,"cik":"0001297000","reported_name":"Scots-Knight Denise","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance Based Restricted Stock Unit","published_at":"2024-09-13T20:49:08.000Z","date":"2024-09-11","kind":"exercise","planned":false,"acquired":false,"shares":188060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"exercise_date":"2024-09-11","expiration_date":"2025-01-25","underlying":"American Depository Shares","underlying_shares":188060},"source":{"system":"sec-edgar","filing":"0000950170-24-106417","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1297000/000095017024106417/ownership.xml","form_type":"4"}},{"id":1407552,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":44173,"kind":"person","name":"Scots-Knight Denise","position":1,"cik":"0001297000","reported_name":"Scots-Knight Denise","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-09-13T20:49:08.000Z","date":"2024-09-11","kind":"exercise","planned":false,"acquired":true,"shares":188060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"security","element":"securityTitle","label":"F3","text":"Reporting Person also beneficially owns 4 ordinary shares, nominal value of GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents performance-based restricted stock unit earned under the Issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on September 11, 2024 based on satisfaction of ADS price threshold values over a two year performance period."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 1,200 ADSs jointly owned by Reporting person and her spouse."}],"balance_after":897578,"source":{"system":"sec-edgar","filing":"0000950170-24-106417","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1297000/000095017024106417/ownership.xml","form_type":"4"}},{"id":1407663,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68213,"kind":"person","name":"Sermon Charles","position":1,"cik":"0001687318","reported_name":"Sermon Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Performance Based Restricted Stock Unit","published_at":"2024-09-13T16:57:13.000Z","date":"2024-09-11","kind":"exercise","planned":false,"acquired":false,"shares":65600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"exercise_date":"2024-09-11","expiration_date":"2025-01-25","underlying":"American Depository Shares","underlying_shares":65600},"source":{"system":"sec-edgar","filing":"0000950170-24-106426","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1687318/000095017024106426/ownership.xml","form_type":"4"}},{"id":1407662,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68213,"kind":"person","name":"Sermon Charles","position":1,"cik":"0001687318","reported_name":"Sermon Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-09-13T16:57:13.000Z","date":"2024-09-11","kind":"exercise","planned":false,"acquired":true,"shares":65600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"security","element":"securityTitle","label":"F3","text":"Reporting Person also beneficially owns 4 ordinary shares, nominal value of GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents performance-based restricted stock unit earned under the Issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on September 11, 2024 based on satisfaction of ADS price threshold values over a two year performance period."}],"balance_after":249987,"source":{"system":"sec-edgar","filing":"0000950170-24-106426","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1687318/000095017024106426/ownership.xml","form_type":"4"}},{"id":1407881,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68235,"kind":"person","name":"Fox Christine Ann","position":1,"cik":"0002005755","reported_name":"Fox Christine Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Performance Based Restricted Stock Unit","published_at":"2024-09-13T16:50:17.000Z","date":"2024-09-11","kind":"exercise","planned":false,"acquired":false,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"exercise_date":"2024-09-11","expiration_date":"2025-01-25","underlying":"American Depository Shares","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-24-106419","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2005755/000095017024106419/ownership.xml","form_type":"4"}},{"id":1407880,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68235,"kind":"person","name":"Fox Christine Ann","position":1,"cik":"0002005755","reported_name":"Fox Christine Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-09-13T16:50:17.000Z","date":"2024-09-11","kind":"exercise","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents performance-based restricted stock unit earned under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on September 11, 2024 based on satisfaction of ADS price threshold values over a two year performance period."}],"balance_after":117571,"source":{"system":"sec-edgar","filing":"0000950170-24-106419","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005755/000095017024106419/ownership.xml","form_type":"4"}},{"id":1407440,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Performance Based Restricted Stock Unit","published_at":"2024-09-13T16:49:18.000Z","date":"2024-09-11","kind":"exercise","planned":false,"acquired":false,"shares":46000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"exercise_date":"2024-09-11","expiration_date":"2025-01-25","underlying":"American Depository Shares","underlying_shares":46000},"source":{"system":"sec-edgar","filing":"0000950170-24-106418","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1553352/000095017024106418/ownership.xml","form_type":"4"}},{"id":1407439,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-09-13T16:49:18.000Z","date":"2024-09-11","kind":"exercise","planned":false,"acquired":true,"shares":46000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents performance-based restricted stock unit earned under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on September 11, 2024 based on satisfaction of ADS price threshold values over a two year performance period."}],"balance_after":94779,"source":{"system":"sec-edgar","filing":"0000950170-24-106418","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553352/000095017024106418/ownership.xml","form_type":"4"}},{"id":1407879,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68234,"kind":"person","name":"Hughes-Wilson Alexandra","position":1,"cik":"0002005875","reported_name":"Hughes-Wilson Alexandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Share Options (Right to buy)","published_at":"2024-09-13T16:47:50.000Z","date":"2024-09-11","kind":"exercise","planned":false,"acquired":false,"shares":75000,"price":1.01,"value":75750.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"240,000 options were issued on 01/25/2023 and 25% of the shares underlying this award became exercisable on January 25, 2024, with the remainder vesting in equal monthly installments thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":1.01,"expiration_date":"2033-01-25","underlying":"American Depository Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000950170-24-106413","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2005875/000095017024106413/ownership.xml","form_type":"4"}},{"id":1407878,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68234,"kind":"person","name":"Hughes-Wilson Alexandra","position":1,"cik":"0002005875","reported_name":"Hughes-Wilson Alexandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Share Options (Right to buy)","published_at":"2024-09-13T16:47:50.000Z","date":"2024-09-11","kind":"exercise","planned":false,"acquired":false,"shares":93333,"price":1.4,"value":130666.2,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"160,000 options were issued on 01/14/2022 and 25% of the shares underlying this award became exercisable on January 14, 2023, with the remainder vesting in equal monthly installments thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":1.4,"expiration_date":"2032-01-14","underlying":"American Depository Shares","underlying_shares":93333},"source":{"system":"sec-edgar","filing":"0000950170-24-106413","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2005875/000095017024106413/ownership.xml","form_type":"4"}},{"id":1407877,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68234,"kind":"person","name":"Hughes-Wilson Alexandra","position":1,"cik":"0002005875","reported_name":"Hughes-Wilson Alexandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Performance Based Restricted Stock Unit","published_at":"2024-09-13T16:47:50.000Z","date":"2024-09-11","kind":"exercise","planned":false,"acquired":false,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":0,"exercise_date":"2024-09-11","expiration_date":"2025-01-25","underlying":"American Depository Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000950170-24-106413","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2005875/000095017024106413/ownership.xml","form_type":"4"}},{"id":1407876,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68234,"kind":"person","name":"Hughes-Wilson Alexandra","position":1,"cik":"0002005875","reported_name":"Hughes-Wilson Alexandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-09-13T16:47:50.000Z","date":"2024-09-11","kind":"exercise","planned":false,"acquired":true,"shares":75000,"price":1.01,"value":75750.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":242881,"source":{"system":"sec-edgar","filing":"0000950170-24-106413","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2005875/000095017024106413/ownership.xml","form_type":"4"}},{"id":1407875,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68234,"kind":"person","name":"Hughes-Wilson Alexandra","position":1,"cik":"0002005875","reported_name":"Hughes-Wilson Alexandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-09-13T16:47:50.000Z","date":"2024-09-11","kind":"exercise","planned":false,"acquired":true,"shares":93333,"price":1.4,"value":130666.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":167881,"source":{"system":"sec-edgar","filing":"0000950170-24-106413","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2005875/000095017024106413/ownership.xml","form_type":"4"}},{"id":1407874,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68234,"kind":"person","name":"Hughes-Wilson Alexandra","position":1,"cik":"0002005875","reported_name":"Hughes-Wilson Alexandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-09-13T16:47:50.000Z","date":"2024-09-11","kind":"exercise","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents performance-based restricted stock unit earned under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on September 11, 2024 based on satisfaction of ADS price threshold values over a two year performance period."}],"balance_after":74548,"source":{"system":"sec-edgar","filing":"0000950170-24-106413","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005875/000095017024106413/ownership.xml","form_type":"4"}},{"id":1424126,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (right to buy)","published_at":"2024-08-23T22:13:05.000Z","date":"2024-08-22","kind":"exercise","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Vests in substantially equal monthly installments over a one year period from the February 8, 2024 grant date. As of June 8, 2024, 15,000 Share Options have vested."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares of the Issuer."}],"balance_after":30000,"derivative":{"exercise_price":3.87,"expiration_date":"2034-02-08","underlying":"American Depository Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000950170-24-100281","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024100281/ownership.xml","form_type":"4"}},{"id":1424125,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (right to buy)","published_at":"2024-08-23T22:13:05.000Z","date":"2024-08-22","kind":"exercise","planned":false,"acquired":false,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Vested in substantially equal monthly installments over a one year period from the February 1, 2023 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":0.94,"expiration_date":"2033-02-01","underlying":"American Depository Shares","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000950170-24-100281","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024100281/ownership.xml","form_type":"4"}},{"id":1424124,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (right to buy)","published_at":"2024-08-23T22:13:05.000Z","date":"2024-08-22","kind":"exercise","planned":false,"acquired":false,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Vested in substantially equal monthly installments over a one year period from the February 1, 2022 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":1.31,"expiration_date":"2032-02-01","underlying":"American Depository Shares","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0000950170-24-100281","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024100281/ownership.xml","form_type":"4"}},{"id":1424123,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (right to buy)","published_at":"2024-08-23T22:13:05.000Z","date":"2024-08-22","kind":"exercise","planned":false,"acquired":false,"shares":31500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Vested in substantially equal monthly installments over a one year period from the February 1, 2021 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":2.72,"expiration_date":"2031-02-01","underlying":"American Depository Shares","underlying_shares":31500},"source":{"system":"sec-edgar","filing":"0000950170-24-100281","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024100281/ownership.xml","form_type":"4"}},{"id":1424122,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (right to buy)","published_at":"2024-08-23T22:13:05.000Z","date":"2024-08-22","kind":"exercise","planned":false,"acquired":false,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Vested in substantially equal monthly installments over a one year period from the February 20, 2020 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":1.84,"expiration_date":"2030-02-20","underlying":"American Depository Shares","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0000950170-24-100281","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024100281/ownership.xml","form_type":"4"}},{"id":1424121,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options (right to buy)","published_at":"2024-08-23T22:13:05.000Z","date":"2024-08-22","kind":"exercise","planned":false,"acquired":false,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Vested in substantially equal monthly installments over a one year period from the July 23, 2019 grant date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares of the Issuer."}],"balance_after":0,"derivative":{"exercise_price":3,"expiration_date":"2029-07-23","underlying":"American Depository Shares","underlying_shares":5500},"source":{"system":"sec-edgar","filing":"0000950170-24-100281","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024100281/ownership.xml","form_type":"4"}},{"id":1424120,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-08-23T22:13:05.000Z","date":"2024-08-22","kind":"sale","planned":false,"acquired":false,"shares":105244,"price":4.4298,"value":466209.8712,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Sale is due to fund administration reasons."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.360 to $4.495, inclusive. The Reporting Person undertakes to provide to Mereo BioPharma Group plc (\"Mereo\"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnote (3) to this Form"}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-100281","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024100281/ownership.xml","form_type":"4"}},{"id":1424119,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-08-23T22:13:05.000Z","date":"2024-08-22","kind":"exercise","planned":false,"acquired":true,"shares":2071,"price":3.87,"value":8014.77,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares of the Issuer."}],"balance_after":105244,"source":{"system":"sec-edgar","filing":"0000950170-24-100281","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024100281/ownership.xml","form_type":"4"}},{"id":1424118,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-08-23T22:13:05.000Z","date":"2024-08-22","kind":"exercise","planned":false,"acquired":true,"shares":43485,"price":0.94,"value":40875.9,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares of the Issuer."}],"balance_after":103173,"source":{"system":"sec-edgar","filing":"0000950170-24-100281","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024100281/ownership.xml","form_type":"4"}},{"id":1424117,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-08-23T22:13:05.000Z","date":"2024-08-22","kind":"exercise","planned":false,"acquired":true,"shares":38953,"price":1.31,"value":51028.43,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares of the Issuer."}],"balance_after":59688,"source":{"system":"sec-edgar","filing":"0000950170-24-100281","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024100281/ownership.xml","form_type":"4"}},{"id":1424116,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-08-23T22:13:05.000Z","date":"2024-08-22","kind":"exercise","planned":false,"acquired":true,"shares":12418,"price":2.72,"value":33776.96,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares of the Issuer."}],"balance_after":20735,"source":{"system":"sec-edgar","filing":"0000950170-24-100281","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024100281/ownership.xml","form_type":"4"}},{"id":1424115,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-08-23T22:13:05.000Z","date":"2024-08-22","kind":"exercise","planned":false,"acquired":true,"shares":6492,"price":1.84,"value":11945.28,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares of the Issuer."}],"balance_after":8317,"source":{"system":"sec-edgar","filing":"0000950170-24-100281","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024100281/ownership.xml","form_type":"4"}},{"id":1424114,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":28580,"kind":"person","name":"PAKIANATHAN DEEPIKA","position":1,"cik":"0001270734","reported_name":"PAKIANATHAN DEEPIKA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-08-23T22:13:05.000Z","date":"2024-08-22","kind":"exercise","planned":false,"acquired":true,"shares":1825,"price":3,"value":5475.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares of the Issuer."}],"balance_after":1825,"source":{"system":"sec-edgar","filing":"0000950170-24-100281","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270734/000095017024100281/ownership.xml","form_type":"4"}},{"id":1468042,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":44173,"kind":"person","name":"Scots-Knight Denise","position":1,"cik":"0001297000","reported_name":"Scots-Knight Denise","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-06-27T20:15:26.000Z","date":"2024-06-26","kind":"sale","planned":false,"acquired":false,"shares":92273,"price":3.3932,"value":313100.7436,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on June 21, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.28 to $3.51, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes 1,200 ADSs jointly owned by Reporting person and her spouse."}],"balance_after":709518,"source":{"system":"sec-edgar","filing":"0000950170-24-078465","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1297000/000095017024078465/ownership.xml","form_type":"4"}},{"id":1468041,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":44173,"kind":"person","name":"Scots-Knight Denise","position":1,"cik":"0001297000","reported_name":"Scots-Knight Denise","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-06-27T20:15:26.000Z","date":"2024-06-25","kind":"sale","planned":false,"acquired":false,"shares":40712,"price":3.6939,"value":150386.0568,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"Reporting Person also beneficially owns 4 ordinary shares, nominal value of GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on June 21, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.60 to $3.805, inclusive. The Reporting Person undertakes to provide to Mereo BioPharma Group plc (\"Mereo\"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (4) and (5) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes 1,200 ADSs jointly owned by Reporting person and her spouse."}],"balance_after":801791,"source":{"system":"sec-edgar","filing":"0000950170-24-078465","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1297000/000095017024078465/ownership.xml","form_type":"4"}},{"id":1468161,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68213,"kind":"person","name":"Sermon Charles","position":1,"cik":"0001687318","reported_name":"Sermon Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-06-27T16:15:47.000Z","date":"2024-06-26","kind":"sale","planned":false,"acquired":false,"shares":32187,"price":3.3932,"value":109216.9284,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on June 21, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.28 to $3.51, inclusive."}],"balance_after":184387,"source":{"system":"sec-edgar","filing":"0000950170-24-078469","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1687318/000095017024078469/ownership.xml","form_type":"4"}},{"id":1468160,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68213,"kind":"person","name":"Sermon Charles","position":1,"cik":"0001687318","reported_name":"Sermon Charles","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-06-27T16:15:47.000Z","date":"2024-06-25","kind":"sale","planned":false,"acquired":false,"shares":14202,"price":3.6939,"value":52460.7678,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"security","element":"securityTitle","label":"F2","text":"Reporting Person also beneficially owns 4 ordinary shares, nominal value of GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on June 21, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.60 to $3.805, inclusive. The Reporting\nPerson undertakes to provide to Mereo BioPharma Group plc (\"Mereo\"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full\ninformation regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (4) and (5) to this Form 4."}],"balance_after":216574,"source":{"system":"sec-edgar","filing":"0000950170-24-078469","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1687318/000095017024078469/ownership.xml","form_type":"4"}},{"id":1467972,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-06-27T16:15:33.000Z","date":"2024-06-26","kind":"sale","planned":false,"acquired":false,"shares":16808,"price":3.3932,"value":57032.9056,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on June 21, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.28 to $3.51, inclusive."}],"balance_after":48779,"source":{"system":"sec-edgar","filing":"0000950170-24-078468","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1553352/000095017024078468/ownership.xml","form_type":"4"}},{"id":1467971,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68173,"kind":"person","name":"Lewicki John A.","position":1,"cik":"0001553352","reported_name":"Lewicki John A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-06-27T16:15:33.000Z","date":"2024-06-25","kind":"sale","planned":false,"acquired":false,"shares":7416,"price":3.6939,"value":27393.9624,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on June 21, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.60 to $3.805, inclusive. The Reporting\nPerson undertakes to provide to Mereo BioPharma Group plc (\"Mereo\"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full\ninformation regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4."}],"balance_after":65587,"source":{"system":"sec-edgar","filing":"0000950170-24-078468","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1553352/000095017024078468/ownership.xml","form_type":"4"}},{"id":1468272,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68235,"kind":"person","name":"Fox Christine Ann","position":1,"cik":"0002005755","reported_name":"Fox Christine Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-06-27T16:15:31.000Z","date":"2024-06-26","kind":"sale","planned":false,"acquired":false,"shares":29439,"price":3.3932,"value":99892.4148,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on June 21, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.28 to $3.51, inclusive."}],"balance_after":57571,"source":{"system":"sec-edgar","filing":"0000950170-24-078467","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2005755/000095017024078467/ownership.xml","form_type":"4"}},{"id":1468271,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68235,"kind":"person","name":"Fox Christine Ann","position":1,"cik":"0002005755","reported_name":"Fox Christine Ann","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-06-27T16:15:31.000Z","date":"2024-06-25","kind":"sale","planned":false,"acquired":false,"shares":12990,"price":3.6939,"value":47983.761,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on June 21, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.60 to $3.805, inclusive. The Reporting\nPerson undertakes to provide to Mereo BioPharma Group plc (\"Mereo\"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4."}],"balance_after":87010,"source":{"system":"sec-edgar","filing":"0000950170-24-078467","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005755/000095017024078467/ownership.xml","form_type":"4"}},{"id":1468269,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68234,"kind":"person","name":"Hughes-Wilson Alexandra","position":1,"cik":"0002005875","reported_name":"Hughes-Wilson Alexandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-06-27T16:15:03.000Z","date":"2024-06-26","kind":"sale","planned":false,"acquired":false,"shares":22968,"price":3.3932,"value":77935.0176,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on June 21, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.28 to $3.51, inclusive."}],"balance_after":34548,"source":{"system":"sec-edgar","filing":"0000950170-24-078462","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2005875/000095017024078462/ownership.xml","form_type":"4"}},{"id":1468268,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":68234,"kind":"person","name":"Hughes-Wilson Alexandra","position":1,"cik":"0002005875","reported_name":"Hughes-Wilson Alexandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-06-27T16:15:03.000Z","date":"2024-06-25","kind":"sale","planned":false,"acquired":false,"shares":10134,"price":3.6939,"value":37433.9826,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the \"Plan\"), that vested on June 21, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.60 to $3.805, inclusive. The Reporting\nPerson undertakes to provide to Mereo BioPharma Group plc (\"Mereo\"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4."}],"balance_after":57516,"source":{"system":"sec-edgar","filing":"0000950170-24-078462","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2005875/000095017024078462/ownership.xml","form_type":"4"}},{"id":1469421,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":44173,"kind":"person","name":"Scots-Knight Denise","position":1,"cik":"0001297000","reported_name":"Scots-Knight Denise","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance Based Restricted Stock Unit","published_at":"2024-06-25T22:15:01.000Z","date":"2024-06-21","kind":"exercise","planned":false,"acquired":true,"shares":282090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."}],"balance_after":188060,"derivative":{"exercise_price":0,"exercise_date":"2024-06-21","expiration_date":"2025-01-25","underlying":"American Depository Shares","underlying_shares":282090},"source":{"system":"sec-edgar","filing":"0000950170-24-077482","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1297000/000095017024077482/ownership.xml","form_type":"4"}},{"id":1469420,"issuer":{"id":7264,"kind":"organization","name":"Mereo BioPharma Group plc"},"owners":[{"id":44173,"kind":"person","name":"Scots-Knight Denise","position":1,"cik":"0001297000","reported_name":"Scots-Knight Denise","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2024-06-25T22:15:01.000Z","date":"2024-06-21","kind":"exercise","planned":false,"acquired":true,"shares":282090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer."},{"field":"security","element":"securityTitle","label":"F3","text":"Reporting Person also beneficially owns 4 ordinary shares, nominal value of GBP 0.003 per ordinary share, of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents performance-based restricted stock unit (\"PSU\") earned under the issuer's 2019 Employee Incentive Plan (the \"Plan\") that vested on June 21, 2024 based on satisfaction of ADS price threshold values over a two year performance period (expiring on January 1, 2025)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 1,200 ADSs jointly owned by Reporting person and her spouse."}],"balance_after":842503,"source":{"system":"sec-edgar","filing":"0000950170-24-077482","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1297000/000095017024077482/ownership.xml","form_type":"4"}}],"next_cursor":"2024-06-25T22:15:01.000000Z,1469420"}